Friday, July 10, 2026

pharma · Asthma · Type 2 Diabetes

AstraZeneca

AstraZeneca is a pharma organization headquartered in Södertälje, SE. Primary therapeutic focus areas include Asthma, Type 2 Diabetes, Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Pulmonary Disease,

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
NMPA registrant Type
Company details
Status
Public
HQ
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
Employees
79,242
Programs
129
Drugs
77
Patents
25
Clinical program

AZD0292

Phase 2 · mab · Bronchiectasis With Pseudomonas Aeruginosa Colonization

AZD0292 for Bronchiectasis With Pseudomonas Aeruginosa Colonization is a Phase 2 program (mab) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Internal code D7700C00003

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
AstraZeneca
Phase
Phase 2
Modality
mab
Indication
Bronchiectasis With Pseudomonas Aeruginosa Colonization
Status
active
Trials
1

Clinical trials